Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

Video

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 is a first-in-class radiopharmaceutical; there is really nothing else like it, says Morris.

Its mechanism of action results in a very low toxicity profile, says Morris. It has very low homological toxicities, and it prolongs life and delays skeletal-related events. It has a lot of potential to be combined with other agents, says Morris.

It is being combined in clinical trials right now with AR-directed therapies. Early studies are also moving forward combining radium-223 with chemotherapy. It cannot be combined with chemotherapy currently, but safety data is forthcoming, says Morris.

It is also being investigated in combination with tumor-directed therapy.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD